AVANIR Pharmaceuticals Phase 3 Drug Meets Main Study Goal; Stock Soars

Bookmark and Share

Reuters -- Avanir Pharmaceuticals Inc said on Tuesday a reformulated version of its Zenvia drug reduced emotional outbursts tied to a little-known neurological disorder, meeting the main goal of a late-stage study and doubling the tiny company’s stock price.

MORE ON THIS TOPIC